INTRODUCTION
Despite improvements in overall survival (OS) with the introduction of adjuvant 5-FU/folinic acid/oxaliplatin treatment for patients with locally advanced stage II and III colorectal cancer (CRC), the management of these patients remains an area of active clinical debate.
Although the molecular targeted agents bevacizumab, cetuximab, panitumumab, aflibercept and ramucrirumab have each improved outcome of CRC patients with metastatic disease, no benefit from these agents have been seen in stage II/III CRC (1, 2) . Understanding the molecular mechanisms of disease progression and resistance to available treatments, with the subsequent development and validation of novel therapeutic strategies, is therefore urgently required in order to develop stratified medicine approaches that individualise patient treatment in stage II/III disease.
EphA2 is a 130kDa glycoprotein receptor and belongs to the largest family of receptor tyrosine kinases (RTK), the Eph family. The Eph family can be divided into two subclasses, EphA and EphB, based on structural homology and affinity for binding either the GPIanchored Ephrin-A or the transmembrane Ephrin-B ligands (3) . Both EphA and EphB contain an extracellular region with an Ephrin binding domain, an epidermal growth factorlike motif and two fibronectin type-III domains as well as a cytoplasmic region including a juxtamembrane segment, the kinase domain, a sterile α-motif (SAM) and a PDZ binding motif (Post synaptic density protein, Drosophila disc large tumor suppressor, and Zonula occludens-1 protein). Eph-Ephrin complexes emanate bidirectional signaling into both Eph expressing cells (forward signaling) and Ephrin-expressing cells (reverse signaling) (4) . In addition to ligand-dependent receptor activation, some studies have shown that even without ligands, Eph receptors, such as EphA2, can form Eph-Eph homodimers and oligomers thus facilitating the formation of signaling Ephrin-Eph heterotetramers (5, 6) . A number of downstream signaling pathways have been linked to Ephrin-Eph complexes, including RAS/MAPK, FAK/SRC, ABL, RHO/RAC/CDC42 and PI3K/AKT/mTOR (7). Among the different EphA receptors, the role of EphA2 in malignant transformation of normal cells, angiogenesis and metastasis has been studied extensively in cancers, particularly in breast, melanoma, glioblastoma and non-small cell lung carcinoma (NSCLC) (8) (9) (10) (11) . The role of EphA2 in invasion/migration and as a potential biomarker and therapeutic target in CRC is however unclear.
In this study, we demonstrate that EphA2 is overexpressed in invasive CRC models and correlates with increased expression of the stem cell marker CD44 in vitro and in clinical samples. We also show that EphA2 expression levels are regulated by KRAS through both the MAPK and RalGDS-RalA pathway and that treatment with EphA2-specific siRNA or recombinant human EFNA1 (rhEFNA1) abrogates migration/invasion of KRASMT CRC cells.
In addition, EphA2 expression was found to be a prognostic biomarker of poor OS in stage II/III CRC. Taken together, our results indicate that EphA2-targeted therapies may represent a promising novel strategy to prevent disease recurrence and progression in stage II/III CRC.
MATERIALS AND METHODS

Materials
MG132 and cycloheximide were obtained from Sigma-Aldrich (Dorset, UK), Trametinib (GSK1120212) and Vemurafenib (PLX4032) from Selleck Chemicals LLC (Suffolk, UK), rhEFNA1 from R&D systems (Abingdon, UK). siRNAs targeting EphA2, EFNA1, KRAS, RalGDS, RalA, RalB, PLCε, TIAM1, PIK3CA were purchased from Qiagen (Crawley, UK). siRNAs targeting AKT1, AKT2, AKT3, p53, p63, p21, c-Src, YES, FYN were obtained from Dharmacon (Chicago, USA). The EphA2 plasmid was a kind gift from Dr. Koichi Miura (Osaka, Japan) (12) .
Cell culture
Authentication and culture of HCT116, HKH-2, DLD-1, Dks-8, LoVo, LS174T, SW620, GP5D, RKO, WiDR, HT-29, LIM2405 and CACO-2 CRC cells have previously been described (13) (14) (15) 
Western blotting
Western blot analysis has previously been described (14, 16) . Anti-EphA2 (Invitrogen), antiRalA (BD Transduction Laboratories, Oxfordshire, UK), anti-CBL (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p53 (Santa Cruz Biotechnology) mouse monoclonal antibodies were used in conjunction with a HRP-conjugated sheep anti-mouse secondary antibody.
Anti-pEphA2
Y588
, anti-pEphA2 S897 , anti-pEphA2
Y772
, anti-RalB, c-Src, YES, and FYN (Cell Signaling) rabbit polyclonal antibodies were used in conjunction with a HRP-conjugated antirabbit secondary antibody. Anti-EphA2 (Cell Signaling) and anti-pTyrosine (Cell Signaling) rabbit antibodies were used for co-immunoprecipitation (IP).
In vitro Migration and Invasion assays
Cell migration and invasion rates were performed as previously described (17) .
Immunofluorescence
Immunofluorescence has previously been described (17) . Anti-EphA2 (Invitrogen, 1:500) mouse monoclonal antibody was used. Transwell indirect co-culture CRC cell -fibroblast indirect co-culture was carried out using a Falcon ® permeable support for 6 well plates with a 0.4μm transparent PET membrane and support companion plates.
Real-time reverse transcription-PCR analysis
RNA was isolated using the GeneJET RNA purification kit (Thermo Scientific, Leicestershire, UK) and reverse transcribed using the Moloney murine leukemia virus-based reverse transcriptase kit (Invitrogen). Q-PCR analysis was performed using the LightCycler ® 480
probes master mix (LightCycler ® 480II, Roche).
siRNA transfections
siRNA transfections were performed as previously described (13) .
Generation of inducible EphA2-silenced CRC cell lines
Inducible EphA2-silenced HCT116 cells were generated as previously described (17) . A pTRIPZ plasmid encoding Tet-inducible shRNA against EphA2 was used (Open Biosystems, Lafayette, United States).
Clinical-pathological data
The study cohort consisted of 509 stage I-IV CRC cases who received resection of the primary tumour at the National University Hospital of Singapore between 1990 and 1999 (18 
Validation cohort
An independent validation dataset was identified and the normalised, log-transformed data was obtained from the Gene Expression Omnibus (GEO) database, accession number GSE17536 (22, 23) . The stage II/III patients were selected (n=114) and the probe set corresponding to EphA2 identified (203499_at). The distribution with respect to EphA2 from the main study (Stage II/III: Low: 49%; High: 51%) was applied to the remaining patients, a patient was therefore labelled as EphA2-low or EphA2-high. The factors age and stage were also extracted as was OS and survival status.
Statistical analysis
The unpaired two-tailed student's t-test was used to determine statistically significant differences between treatment effects and calculated using GraphPad Prism version 5 for 
RESULTS
Oncogenic KRAS is associated with high EphA2 expression levels in CRC cell lines.
Previous KRAS siRNA screens from our lab have identified the RTK EphA2 as a potential KRAS target gene in KRASMT CRC cells (15) . Based on these results, we analysed EphA2 expression and phosphorylation levels in the KRASMT HCT116 and DLD-1 and KRASWT HKH-2 and Dks-8 isogenic paired cell line models using Western blotting and coimmunoprecipitation (24) . Constitutive EphA2 levels were significantly higher in the KRASMT HCT116 and DLD-1 cells compared to their KRASWT counterparts ( Fig. 1A ; Supplementary   Fig. S1A ). Phosphorylation levels of EphA2 at Y772 (tyrosine residue within the activation loop), S897 (ligand-independent serine residue) and Y588 (tyrosine residue located in the juxtamembrane region which controls its kinase activity) were likewise higher in KRASMT cells compared to their isogenic WT clones, suggesting that EphA2 is actively signaling in the KRASMT models (25) (26) (27) . We also found increased EphA2 mRNA levels in the HCT116 cells compared to its WT clone ( Supplementary Fig. S1C ). These data would suggest that in addition to differences in transcriptional regulation, the increased EphA2 levels in KRASMT HCT116 are a result of decreased protein turn-over and increased protein stability.
Recent studies in lung cancer and glioma have suggested a role for EphA2 in regulating cancer stem-like properties (29, 30) . Interestingly, we found that expression of CD44, a marker associated with CRC stem cells (31) , was higher in KRASMT cells and correlated with high expression levels of EphA2 ( Fig. 1A; Supplementary Fig. S1D ). We also found high expression and phosphorylation levels of EphA2 and CD44 in a panel of non-matched KRASMT and BRAFMT CRC compared to KRASWT/BRAFWT CRC cells (Fig. 1C) .
The RAS/MEK and RAS/RalGDS/RalA pathways regulate EphA2 expression levels.
Given the differential expression of EphA2 in KRASMT, BRAFMT and KRASWT CRC cells, we hypothesized that KRAS may directly affect EphA2 expression. siRNA against KRAS or treatment with the MEK1/2 inhibitor GSK1120212 resulted in strong decreases in EphA2 mRNA and protein levels and significant increases in EFNA1 mRNA levels in KRASMT HCT116 cells (Fig. 2A) . Similar results were also obtained in a panel of KRASMT and BRAFMT CRC cells using GSK1120212 (Supplementary Fig. S2A ). Interestingly, treatment with the BRAF inhibitor Vemurafenib decreased EphA2 levels in BRAFMT cells, but not in KRASMT cells ( Supplementary Fig. S2B) ; the sustained MAPK signaling following Vemurafenib or siBRAF in the KRASMT CRC cells is consistent with previous studies showing that inhibition of BRAF in the presence of oncogenic RAS induces BRAF binding to CRAF, leading to CRAF hyper-activation and sustained MEK1/2-ERK1/2 activation (32).
Furthermore, RNAi against KRAS resulted in more potent inhibition of EphA2 expression compared to the effects of siERK1, siERK2 or combined siERK1/2, indicating that other KRAS effector pathways may regulate EphA2 expression ( Fig. 2A) PLCε, TIAM1 and RalGDS and found that EphA2 levels were potently decreased by RalGDS gene silencing, whereas silencing of the other major RAS effectors did not significantly affect EphA2 levels ( Fig. 2B; Supplementary Fig. S2C ). RALGDS is a Guanine nucleotide Exchange Factor (GEF), coupling RAS to the GTPases RalA and RalB (33) . Silencing of RalA, but not RalB, resulted in significant decreases in EphA2 mRNA and protein levels in HCT116 and DLD-1 cells (Fig. 2C ; data not shown). There was no effect of siRalA on EFNA1 mRNA expression levels ( Supplementary Fig. S2D ). We also explored a potential regulation of EphA2 by p53 or the Src family kinases (SFK), using RNAi and the isogenic HCT116-p53wt, HCT116-p53 null (-/-), HCT116-p53 (+/-), HCT116-p53 (R248W/-) and HCT116-p53 (R248W/+) cells. These data showed that EphA2 is not regulated by p53 or the SFKs (Supplementary Fig. S2E and F). Taken together, these results would indicate that KRAS regulates EphA2 expression through both the MAPK and RalGDS-RalA pathways in KRASMT CRC models (Fig. 2D ).
EphA2 regulates migration and invasion in CRC. Previous studies have shown a role for
EphA2 in invasion and metastasis in breast, glioblastoma and NSCLC (9, 25, 30) . To investigate a potential role for EphA2 in invasion and migration in CRC, we initially assessed expression and phosphorylation levels of EphA2 in the KRASMT, KRASWT (HKH-2) and KRASMT/+chr3 HCT116 parental and invasive sublines, previously generated in our lab using Matrigel Invasion Chambers (17) . We found significant increases in EphA2 mRNA and protein expression and phosphorylation levels in the invasive HCT116, HKH-2 and HCT116+Chr3 sub-lines compared to their parental cells, and this was associated with markedly increased CD44 expression levels ( Fig. 3A; Supplementary Fig. S3A ). In addition, we also found marked decreases in EFNA1 mRNA levels in the HKH-2 invasive cells, compared to its parental cell line ( Supplementary Fig. S3A ). Silencing of EphA2 significantly reduced basal migration and invasion rates in KRASMT HCT116, DLD-1 and LoVo cells and in the invasive HCT116 and HKH-2 cells ( Fig. 3A; Supplementary Fig. S3B ; data not shown). 
We also established doxycycline-inducible EphA2 shRNA clones and assessed the effect of EphA2 targeting on migration. Treatment of two individual EphA2 shRNA clones with doxycycline for 72h resulted in potent decreases in migration rates similar to those observed with siRNA (Fig. 3A) . Furthermore, the CD44 + subpopulation was significantly reduced in the corresponding EphA2 knockdown cells (Supplementary Fig. S3C ). Importantly, transient over-expression of exogenous EphA2 resulted in increased invasion and migration of CRC cells ( Fig. 3B; Supplementary Fig. S3D ).
Our group has previously shown that exposure to 5-FU significantly increases both migration and invasion of CRC cells (17) . We now show that 5-FU treatment results in acute increases in EphA2 expression levels and that silencing of EphA2 abrogates the increased migratory potential following 5-FU treatment in CRC cells (Fig. 3B ).
We also investigated the effect of the EphA2 ligand EFNA1 on CRC cell migration.
Incubation of HCT116 cells with rhEFNA1 increased EphA2 tyrosine phosphorylation and resulted in EphA2 internalization and decreased protein expression after 15min and 30min respectively (Fig. 3C , upper-middle panel; Supplementary Fig. S3E ). Immunoprecipitation experiments confirmed that EphA2 interacts with c-Cbl (an ubiquitin E3 ligase) in HCT116
following incubation with rhEFNA1 for 15 minutes (Fig. 3C, lower panel) . Moreover, pretreatment with the proteasome inhibitor MG132 attenuated rhEFNA1-induced EphA2 downregulation, providing further evidence that EphA2 downregulation is mediated by the ubiquitin proteasome system (Fig. 3C, lower panel) . Importantly, incubation of CRC cells with rhEFNA1 significantly reduced basal migration rates in HCT116, DLD-1 and LoVo KRASMT cells, similar to those observed with RNAi against EphA2 ( Fig. 3D ; Supplementary   Fig. S3F ).
In view of our previous data showing that RalA regulates EphA2 expression levels, we also determined the effect of siRalA on migration of KRASMT CRC cells. Silencing of RalA 
significantly reduced basal migration rates in HCT116, DLD-1 and LoVo cells ( Fig. 3D;   Supplementary Fig. S3F ). Collectively, all these data provide strong evidence that EphA2 is an important mediator of migration and invasion in CRC and that down-regulating EphA2 using RNAi or rhEFNA1 or by blocking upstream regulators of EphA2 expression, such as RalA, abrogates migration of KRASMT CRC cells. II-III) CRC samples by IHC (21) . EphA2 was found to be highly expressed in colorectal adenocarcinoma compared to matched normal colon tissue (Fig. 4A) . In contrast to our preclinical models, no correlation between KRAS mutational status and EphA2 expression levels was found within this dataset (data not shown). High EphA2 expression levels were also found in a second TMA including 509 stage I-IV CRC samples ( Supplementary Fig.   S4A ) (18) . In support of our preclinical data, a strong correlation was found between EphA2 expression and the stem-cell markers CD44 (p < 0.001) and Lgr5 (p < 0.001), both in the entire patient cohort and when the early stage II/III colorectal tumours were considered alone ( (Table 2B ). In contrast, there was no significant association between EphA2 expression and prognosis in the resection/adjuvant chemotherapy cohort, suggesting a treatment interaction effect ( Supplementary Fig. S4B and S4C and S5).
EphA2 is differentially expressed in CRC versus
matched normal tissue. To investigate the clinical importance of EphA2 in CRC, we assessed EphA2 expression in 211 (stage
Independent validation of EphA2 as poor prognostic biomarker in CRC.
The prognostic role of EphA2 expression in CRC was validated using a publicly-available stage II/III (n=114) CRC microarray dataset (GSE17536) (17, 34) . Analysis of EphA2 mRNA expression in this dataset revealed a significant association between high EphA2 expression and decreased OS (p=0.0277) (Fig. 4C, right whether the tumour microenvironment could influence EphA2 levels in KRASWT models.
We found markedly increased EphA2 levels in the KRASWT HKH-2, DiFi, OXCO2 and Dks-8 cells following incubation with recombinant human EGF, TGF-α or HGF, thus supporting the idea that microenvironment-derived ligands can regulate EphA2 levels in KRASWT CRC (Fig. 4D, left panel; Supplementary Fig. S6A ). In addition, incubation of HKH-2 cells with conditioned medium from CCD-18Co colon fibroblasts, or co-culture of HKH-2 cells with CCD-18Co cells, resulted in potent increases in EphA2 expression levels in the HKH-2 cell line (Fig. 4D, right panel; Supplementary Fig. S6B ). Moreover, silencing of KRAS abrogated co-culture-induced EphA2 expression levels in HKH-2 cells, indicating that RAS activation is required for the EphA2 increases following co-culture in KRASWT CRC cells (Fig. 4D ).
Clinically, a significant positive association between TGF-α mRNA and EphA2 mRNA levels was observed in 4 independent CRC online datasets, further supporting the hypothesis that stromal-derived growth factors can regulate EphA2 expression levels in an in vivo setting (Supplementary Table S5 ). Our study showed that high EphA2 expression significantly correlated with high expression levels of CD44 and Lgr5 in CRC tissues. Furthermore, shRNA mediated knockdown of EphA2 suppressed the CD44-high stem-like CRC cell population, indicating that EphA2 may be a promising target to prevent CRC recurrence and metastasis.
DISCUSSION
In order to model colorectal tumour cell invasion/metastasis, our group has previously generated invasive (KRASMT/KRASWT/+chr3) CRC daughter cells which displayed an epithelial-mesenchymal transition-like phenotype, high levels of CD44 and increased colonyforming ability (17) . We now show that EphA2 is highly expressed in these invasive daughter cell lines and that si/shRNA mediated knockdown of EphA2 potently inhibited migration and invasion of parental and invasive CRC cells. In agreement with previous studies, we found that EphA2 was rapidly internalized and downregulated in a proteasome-dependent manner in response to EFNA1-ligand stimulation and this resulted in potent inhibition of migration in a panel of CRC cells (42) . These data would indicate that EphA2 is an important regulator of migration and invasion in CRC.
A key finding of our study is that high EphA2 expression was significantly associated with poorer OS in stage II/III CRC. Importantly, further univariate and multivariate analyses Given its potential role in CRC progression and metastasis, we further investigated how EphA2 expression levels are regulated in CRC. In contrast to previous studies, our data did not show a role for p53 or the Src Family Kinases in regulating EphA2 expression (44, 45) .
Using a systems biology approach, we previously identified EphA2 as a potential KRAS target in KRASMT CRC cells (15) . In agreement with previous studies in breast cancer and melanoma, our examination of a large panel of CRC cells revealed high EphA2 expression in cells harbouring an activating mutation in KRAS or BRAF compared to KRAS/BRAFWT cells (28, 46) . Inhibition of the MAPK pathway resulted in significant increased EFNA1 mRNA expression while reducing EphA2 mRNA and protein levels. These data and our results using RNAi-mediated knockdown of EFNA1 or recombinant EFNA1, would indicate that expression of EFNA1 contributes, at least in part, to EphA2 levels in CRC, consistent with previous findings in breast cancer (28) . In contrast to the in vitro data, no correlation between the KRAS mutational status and EphA2 levels was found in our clinical samples. However, our data would suggest that microenvironment-derived ligands can regulate EphA2 levels in KRASWT tumours, which could explain why EphA2 levels were not significantly higher in the KRASMT CRC samples.
In conclusion, using preclinical CRC models and patient tissue samples, we have identified 
